Dialysis patients may get safer dosing for common infection drug
NCT ID NCT06093269
First seen Dec 11, 2025 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This study looks at how the antibiotic cefazolin behaves in the blood of people on chronic hemodialysis who have catheter infections. Researchers will take blood samples at different times to measure drug levels. The goal is to find the best dose to treat infections while avoiding side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTION, BACTERIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of hemodialysis, University Hospital of Tours
Orléans, 45100, France
-
Department of hemodialysis, University Hospital of Tours
Tours, 37044, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cefazolin
What this could lead to
If successful, this could help doctors give the right dose of cefazolin to hemodialysis patients, improving infection treatment and reducing side effects.
What could go wrong
This is a small, early-phase study with only 32 participants, so results may not apply to all patients. It focuses on drug levels, not direct treatment outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.